NYSE:TEVA
Teva Pharmaceutical (TEVA)
34.46
+0.24 (0.70%)
as of Jun 25, 2026, 2:16:03 pm Market Open.
69 watching
Financials 
Technical Analysis 0
Investor Insights
Jun 25, 2026, 12:00 amThis summary was created by AI, based on 3 opinions in the last 12 months.
Teva Pharmaceutical has shown significant improvement in its stock performance, with a notable increase of 264% since the beginning of 2023 under the leadership of its current CEO. Despite the challenges posed by the rising competition in the generic market, particularly for GLP drugs, the demand for these products remains robust. Innovations in drug formulations, such as pill-shaped GLPs, suggest a potential for future growth, yet experts highlight concerns about Teva's innovative capabilities. The company has been experiencing strong accumulation in recent months, breaking through key price resistance levels. Analysts project a price target of $34.50, though Teva currently does not offer dividends.
Consensus
Positive
Valuation
Undervalued
Similar
Pfeizer,PFE
TOP PICK
A long time favourite. It is the largest generic pharmaceutical company.
They will be able to benefit from the aging population and government wanting more generic prescriptions. He bought this stock in the low 30's.
Norman LevineOwned
biotechnologypharmaceutical
BUY
TOP PICK
Sitting by its all-time high even in this poor market. Largest generic drug manufacturer in the world. A major beneficiary of an economic slowdown because people will switch from branded products to generics. Major beneficiary of drugs coming off patent.
Norman LevineOwned
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick July 25/06. Up 42%.) Still a Buy. The biggest generic drug manufacturer in the world.
Norman LevineOwned
biotechnologypharmaceutical
TOP PICK
World's largest generic drug manufacturer. Has gone from being a growth stock to a value stock. A lot more patented drugs will be coming off in 2007 and 2008.
Norman LevineOwned
biotechnologypharmaceutical
BUY
World’s largest generic drug manufacturer. Also have their own branded drug division. Made some acquisitions and is going through some digestion, but a year from now the stock should be significantly higher.
Norman LevineOwned
biotechnologypharmaceutical
BUY
World’s largest generic drug manufacturer. A value stock. Has a great pipeline of new drugs coming out in the next few years, both generic and its own proprietary drugs. Pfizer’s (PFE-N) Lipitor drug does not come off patent until 2011.
Norman LevineOwned
biotechnologypharmaceutical
BUY
World’s largest generic drug manufacturer with most sales in North America. Reported great earnings, but stock has acted poorly lately because next year’s growth is not going to be as big. Good price.
Norman LevineOwned
biotechnologypharmaceutical
TOP PICK
World's largest generic drug manufacturer. Gone from being a growth stock to a value stock. Merck and Pfizer have come out with their own generics when their drugs came off patent. Based in Israel. The drop in price gives a good opportunity.
Norman LevineOwned
biotechnologypharmaceutical
BUY
Largest generic drug manufacturer in the world. Likes long-term outlook for generics. Emerging markets have come off which affected the stock. Bit of a tumult on drugs coming off patent with original patent owners issuing drugs for less than generics. A temporary phenomena and this company will again be on top.
Norman LevineOwned
biotechnologypharmaceutical
WAIT
In the top 2 of the world's generic drug manufacturers. Interesting dynamics going on in the healthcare sector. When the patent came off Zocor, Merck (MRK-N) lowered their price below the generic price. This was a first but other companies could follow this tactic so, he is staying on the sidelines. Recently sold his holdings.
biotechnologypharmaceutical
PAST TOP PICK
(A Top Pick May 30/05. Up 4%.) Trading at a lower multiple and is a bigger stronger company than it was a year ago. Has more new business going for them. Still attractive.
Neil WickhamOwned
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
